Evidence map›Paper›PMID 41958190›Full record

ArticleMolecular pharmaceutics2026

Sustained Release of Carvacrol Aldehyde from Hydroxyapatite for Osteosarcoma Inhibition.

Aditi Dahiya, Susmita Bose

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Aditi DahiyaW. M. Keck Biomedical Materials Research Laboratory, School of Mechanical and Materials Engineering, Washington State University, Pullman, Washington 99164, United States.ORCID 0000-0001-5009-3952
Susmita BoseW. M. Keck Biomedical Materials Research Laboratory, School of Mechanical and Materials Engineering, Washington State University, Pullman, Washington 99164, United States.ORCID 0000-0001-8601-016X

Funding

3D Printed Calcium Phosphate Scaffolds with Natural Medicinal Compounds for Dental ApplicationsR01DE029204 · NIDCR · WASHINGTON STATE UNIVERSITY · PI BOSE, SUSMITA · 2020 to 2024
$1.7M
Surface Modified Metal Implant Using doped HydroxyapatiteR56AR066361 · NIAMS · WASHINGTON STATE UNIVERSITY · PI BOSE, SUSMITA · 2022 to 2024
$638k
NIAMS NIH HHS R56 AR066361NIDCR NIH HHS R01 DE029204
6 · The paper itself

Abstract

The clinical management of bone cancer and infections remains a critical challenge due to limitations in localized drug delivery and rising antibiotic resistance. In our previous studies, we demonstrated carvacrol's (CA) osteogenic and antibacterial potential when loaded onto 3D-printed TCP scaffolds. However, the rapid release and limited retention of CA restricted long-term efficacy. Herein, we develop a hydroxyapatite (HA) substrate to locally deliver CA and its aldehyde derivative (carvacrol aldehyde) (CA-CHO) to enhance its biological properties. CA-CHO is synthesized via SnCl

Indexed as

AldehydesBone NeoplasmsCymenesDurapatiteOsteosarcomaAnti-Bacterial AgentsCell Line, TumorCell SurvivalDelayed-Action PreparationsDrug LiberationHumansOsteoblastsStaphylococcus aureusAldehydesAnti-Bacterial AgentscarvacrolCymenesDelayed-Action PreparationsDurapatitebacterial inhibitionbone tissue engineeringcarvacrol derivativeshydroxyapatiteosteosarcomasynthesis

Identifiers

PMID41958190
PMCPMC13182677

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.